Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis

Saori Nagao, Kazuaki Taguchi, Hiromi Sakai, Ryota Tanaka, Hirohisa Horinouchi, Hiroshi Watanabe, Koichi Kobayashi, Masaki Otagiri, Toru Maruyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects. We report herein on the preparation of a nanotechnology-based CO donor, CO-bound hemoglobin-vesicles (CO-HbV). We hypothesized that CO-HbV could have a therapeutic effect on idiopathic pulmonary fibrosis (IPF), an incurable lung fibrosis, that is thought to involve inflammation and the production of reactive oxygen species (ROS). Pulmonary fibril formation and respiratory function were quantitatively evaluated by measuring hydroxyproline levels and forced vital capacity, respectively, using a bleomycin-induced pulmonary fibrosis mice model. CO-HbV suppressed the progression of pulmonary fibril formation and improved respiratory function compared to saline and HbV. The suppressive effect of CO-HbV on pulmonary fibrosis can be attributed to a decrease in ROS generation by inflammatory cells, NADPH oxidase 4 and the production of inflammatory cells, cytokines and transforming growth factor-β in the lung. This is the first demonstration of the inhibitory effect of CO-HbV on the progression of pulmonary fibrosis via the anti-oxidative and anti-inflammatory effects of CO in the bleomycin-induced pulmonary fibrosis mice model. CO-HbV has the potential for use in the treatment of, not only IPF, but also a variety of other ROS and inflammation-related disorders.

Original languageEnglish
Pages (from-to)6553-6562
Number of pages10
JournalBiomaterials
Volume35
Issue number24
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Pulmonary Fibrosis
Hemoglobin
Bleomycin
Carbon Monoxide
Carbon monoxide
Hemoglobins
Reactive Oxygen Species
Lung
Idiopathic Pulmonary Fibrosis
Oxygen
Anti-Inflammatory Agents
Hydroxyproline
Inflammation
Nanotechnology
NADPH Oxidase
Vital Capacity
Transforming Growth Factors
Therapeutic Uses
Oxidants
Fibrosis

Keywords

  • Antioxidant
  • Fibrosis
  • Inflammation
  • Liposome
  • Lung

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Nagao, S., Taguchi, K., Sakai, H., Tanaka, R., Horinouchi, H., Watanabe, H., ... Maruyama, T. (2014). Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. Biomaterials, 35(24), 6553-6562. https://doi.org/10.1016/j.biomaterials.2014.04.049

Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. / Nagao, Saori; Taguchi, Kazuaki; Sakai, Hiromi; Tanaka, Ryota; Horinouchi, Hirohisa; Watanabe, Hiroshi; Kobayashi, Koichi; Otagiri, Masaki; Maruyama, Toru.

In: Biomaterials, Vol. 35, No. 24, 01.01.2014, p. 6553-6562.

Research output: Contribution to journalArticle

Nagao, S, Taguchi, K, Sakai, H, Tanaka, R, Horinouchi, H, Watanabe, H, Kobayashi, K, Otagiri, M & Maruyama, T 2014, 'Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis', Biomaterials, vol. 35, no. 24, pp. 6553-6562. https://doi.org/10.1016/j.biomaterials.2014.04.049
Nagao, Saori ; Taguchi, Kazuaki ; Sakai, Hiromi ; Tanaka, Ryota ; Horinouchi, Hirohisa ; Watanabe, Hiroshi ; Kobayashi, Koichi ; Otagiri, Masaki ; Maruyama, Toru. / Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. In: Biomaterials. 2014 ; Vol. 35, No. 24. pp. 6553-6562.
@article{19794b780d47487185ea1275b32f8feb,
title = "Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis",
abstract = "Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects. We report herein on the preparation of a nanotechnology-based CO donor, CO-bound hemoglobin-vesicles (CO-HbV). We hypothesized that CO-HbV could have a therapeutic effect on idiopathic pulmonary fibrosis (IPF), an incurable lung fibrosis, that is thought to involve inflammation and the production of reactive oxygen species (ROS). Pulmonary fibril formation and respiratory function were quantitatively evaluated by measuring hydroxyproline levels and forced vital capacity, respectively, using a bleomycin-induced pulmonary fibrosis mice model. CO-HbV suppressed the progression of pulmonary fibril formation and improved respiratory function compared to saline and HbV. The suppressive effect of CO-HbV on pulmonary fibrosis can be attributed to a decrease in ROS generation by inflammatory cells, NADPH oxidase 4 and the production of inflammatory cells, cytokines and transforming growth factor-β in the lung. This is the first demonstration of the inhibitory effect of CO-HbV on the progression of pulmonary fibrosis via the anti-oxidative and anti-inflammatory effects of CO in the bleomycin-induced pulmonary fibrosis mice model. CO-HbV has the potential for use in the treatment of, not only IPF, but also a variety of other ROS and inflammation-related disorders.",
keywords = "Antioxidant, Fibrosis, Inflammation, Liposome, Lung",
author = "Saori Nagao and Kazuaki Taguchi and Hiromi Sakai and Ryota Tanaka and Hirohisa Horinouchi and Hiroshi Watanabe and Koichi Kobayashi and Masaki Otagiri and Toru Maruyama",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.biomaterials.2014.04.049",
language = "English",
volume = "35",
pages = "6553--6562",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "24",

}

TY - JOUR

T1 - Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis

AU - Nagao, Saori

AU - Taguchi, Kazuaki

AU - Sakai, Hiromi

AU - Tanaka, Ryota

AU - Horinouchi, Hirohisa

AU - Watanabe, Hiroshi

AU - Kobayashi, Koichi

AU - Otagiri, Masaki

AU - Maruyama, Toru

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects. We report herein on the preparation of a nanotechnology-based CO donor, CO-bound hemoglobin-vesicles (CO-HbV). We hypothesized that CO-HbV could have a therapeutic effect on idiopathic pulmonary fibrosis (IPF), an incurable lung fibrosis, that is thought to involve inflammation and the production of reactive oxygen species (ROS). Pulmonary fibril formation and respiratory function were quantitatively evaluated by measuring hydroxyproline levels and forced vital capacity, respectively, using a bleomycin-induced pulmonary fibrosis mice model. CO-HbV suppressed the progression of pulmonary fibril formation and improved respiratory function compared to saline and HbV. The suppressive effect of CO-HbV on pulmonary fibrosis can be attributed to a decrease in ROS generation by inflammatory cells, NADPH oxidase 4 and the production of inflammatory cells, cytokines and transforming growth factor-β in the lung. This is the first demonstration of the inhibitory effect of CO-HbV on the progression of pulmonary fibrosis via the anti-oxidative and anti-inflammatory effects of CO in the bleomycin-induced pulmonary fibrosis mice model. CO-HbV has the potential for use in the treatment of, not only IPF, but also a variety of other ROS and inflammation-related disorders.

AB - Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects. We report herein on the preparation of a nanotechnology-based CO donor, CO-bound hemoglobin-vesicles (CO-HbV). We hypothesized that CO-HbV could have a therapeutic effect on idiopathic pulmonary fibrosis (IPF), an incurable lung fibrosis, that is thought to involve inflammation and the production of reactive oxygen species (ROS). Pulmonary fibril formation and respiratory function were quantitatively evaluated by measuring hydroxyproline levels and forced vital capacity, respectively, using a bleomycin-induced pulmonary fibrosis mice model. CO-HbV suppressed the progression of pulmonary fibril formation and improved respiratory function compared to saline and HbV. The suppressive effect of CO-HbV on pulmonary fibrosis can be attributed to a decrease in ROS generation by inflammatory cells, NADPH oxidase 4 and the production of inflammatory cells, cytokines and transforming growth factor-β in the lung. This is the first demonstration of the inhibitory effect of CO-HbV on the progression of pulmonary fibrosis via the anti-oxidative and anti-inflammatory effects of CO in the bleomycin-induced pulmonary fibrosis mice model. CO-HbV has the potential for use in the treatment of, not only IPF, but also a variety of other ROS and inflammation-related disorders.

KW - Antioxidant

KW - Fibrosis

KW - Inflammation

KW - Liposome

KW - Lung

UR - http://www.scopus.com/inward/record.url?scp=84901387053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901387053&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.04.049

DO - 10.1016/j.biomaterials.2014.04.049

M3 - Article

C2 - 24811261

AN - SCOPUS:84901387053

VL - 35

SP - 6553

EP - 6562

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 24

ER -